424 related articles for article (PubMed ID: 16504986)
1. Apolipoproteins as markers and managers of coronary risk.
Chan DC; Watts GF
QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
[TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
[TBL] [Abstract][Full Text] [Related]
3. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
Walldius G; Jungner I
Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
[TBL] [Abstract][Full Text] [Related]
4. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
[TBL] [Abstract][Full Text] [Related]
5. The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease.
Khadem-Ansari MH; Rasmi Y; Rahimi-Pour A; Jafarzadeh M
Singapore Med J; 2009 Jun; 50(6):610-3. PubMed ID: 19551315
[TBL] [Abstract][Full Text] [Related]
6. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
Andrikoula M; McDowell IF
Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887
[TBL] [Abstract][Full Text] [Related]
7. [Apolipoproteins are new and better risk indicators of myocardial infarction].
Walldius G; Jungner I
Lakartidningen; 2004 Mar; 101(13):1188-94. PubMed ID: 15101244
[TBL] [Abstract][Full Text] [Related]
8. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.
Walldius G; Jungner I
J Intern Med; 2006 May; 259(5):493-519. PubMed ID: 16629855
[TBL] [Abstract][Full Text] [Related]
9. Role of lipid and lipoprotein profiles in risk assessment and therapy.
Ballantyne CM; Hoogeveen RC
Am Heart J; 2003 Aug; 146(2):227-33. PubMed ID: 12891189
[TBL] [Abstract][Full Text] [Related]
10. Apolipoproteins A-I and B-markers in coronary risk evaluation.
Agoston-Coldea L; Zdrenghea D; Pop D; Crăciun A; Rusu ML; Mocan T
Rom J Intern Med; 2007; 45(3):251-8. PubMed ID: 18333357
[TBL] [Abstract][Full Text] [Related]
11. ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men. Results from the 1-year randomized Oslo Diet and Exercise Study.
Holme I; Høstmark AT; Anderssen SA
J Intern Med; 2007 Aug; 262(2):235-43. PubMed ID: 17645591
[TBL] [Abstract][Full Text] [Related]
12. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
Walldius G; Jungner I; Aastveit AH; Holme I; Furberg CD; Sniderman AD
Clin Chem Lab Med; 2004; 42(12):1355-63. PubMed ID: 15576296
[TBL] [Abstract][Full Text] [Related]
13. Effect of antiatherogenic L-aspartate and L-glutamate on serum lipoproteins cholesterol and apolipoproteins A-1 and B in rabbits fed with high cholesterol diet.
Yanni AE; Perrea DN; Yatzidis HA
Nutr Metab Cardiovasc Dis; 2005 Jun; 15(3):161-5. PubMed ID: 15955463
[TBL] [Abstract][Full Text] [Related]
14. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?
Sniderman A; McQueen M; Contois J; Williams K; Furberg CD
J Clin Lipidol; 2010; 4(3):152-5. PubMed ID: 21122647
[TBL] [Abstract][Full Text] [Related]
15. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.
Sniderman AD; Jungner I; Holme I; Aastveit A; Walldius G
J Intern Med; 2006 May; 259(5):455-61. PubMed ID: 16629851
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a) levels are increased in healthy young subjects with parental history of premature myocardial infarction.
Gaeta G; Cuomo S; Capozzi G; Foglia MC; Barra S; Madrid A; Stornaiuolo V; Trevisan M
Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):492-6. PubMed ID: 17962002
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein B and non-high-density lipoprotein cholesterol are better risk markers for coronary artery disease than low-density lipoprotein cholesterol in hypertriglyceridemic metabolic syndrome patients.
Boumaiza I; Omezzine A; Rejeb J; Rebhi L; Kalboussi N; Ben Rejeb N; Nabli N; Ben Abdelaziz A; Boughazala E; Bouslama A
Metab Syndr Relat Disord; 2010 Dec; 8(6):515-22. PubMed ID: 20715933
[TBL] [Abstract][Full Text] [Related]
18. Strategies for optimizing lipid management.
Ballantyne CM
Postgrad Med; 2004 Sep; 116(3 Suppl):13-20. PubMed ID: 19667671
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of selected risk factors of atherosclerosis in children with type 1 diabetes mellitus and hypercholesterolemia].
Muchacka-Bianga M; Deja G; Jarosz-Chobot P; Małecka-Tendera E; Kalina M; Grychtoł M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):25-30. PubMed ID: 16704858
[TBL] [Abstract][Full Text] [Related]
20. A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia.
Al-Bahrani AI; Bakhiet CS; Bayoumi RA; Al-Yahyaee SA
Diabetes Res Clin Pract; 2005 Jul; 69(1):44-51. PubMed ID: 15904989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
